Participants are assigned by chance to receive either EIK1001 with pembrolizumab and chemotherapy, or a placebo with pembrolizumab and chemotherapy. The study is done in different parts and includes two doses of EIK1001 to help find the best dose. Treatment is given over time, with regular study visits and follow-up while the cancer and side effects are watched.

The main purpose of the study is to compare how well the treatment combinations work and how safe they are. Progression-free survival means the time before the cancer gets worse or the person dies, and overall survival means the time before death from any cause. The study also looks at side effects and whether treatment has to be stopped because of them.

The purpose of this research is to determine if using THIO followed by cemiplimab helps patients with advanced NSCLC live longer compared to using standard chemotherapy alone. Both treatments are given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein.

During the study, patients will be randomly assigned to receive either the THIO/cemiplimab combination or one of the standard chemotherapy medications. The treatment period may continue for up to 24 months. Throughout the study, doctors will monitor patients’ health and track how their cancer responds to the treatment. They will also watch for any side effects that may occur during the treatment period.

The main goal is to see how well the first set of medicines controls the cancer and to assess how the second‑line medicines affect breathing problems caused by the lung disease. Participants receive a series of intravenous infusions over several weeks, followed by regular check‑ups that include blood tests and imaging. Imaging is performed with a CT scan, which is a special X‑ray that creates detailed pictures of the lungs and chest.

After the initial treatment period, patients are monitored for up to six months to record any worsening of breathing that might require stopping the medication, as well as overall health outcomes such as how long the disease stays stable and overall survival. All side effects are recorded and graded according to standard cancer‑treatment safety guidelines. The study follows a set schedule of clinic visits, drug administration, and imaging assessments.

Participants in the study will receive these medications through intravenous infusion, which means the medicine is delivered directly into a vein. The research is divided into different stages to determine the safest and most effective dose of the medicine. During the first part, the focus is on how well the body tolerates the combination of drugs. The subsequent parts aim to see how well the treatments work to reduce the size or growth of the tumors.

The treatments involve medications administered through an Intravenous line, which is a method of delivering medicine directly into a vein. One group receives the study drug PF-08634404 along with a combination of chemotherapy drugs, which may include Paclitaxel, Carboplatin, or Pemetrexed. Another group receives Pembrolizumab combined with these chemotherapy drugs. Some participants may also receive Paclitaxel Albumin-Bound or a Placebo involving Sodium Chloride. During the study, participants will be monitored to see how they respond to the medicines and to track their Overall Survival and Progression-Free Survival, which refers to the length of time during and after treatment that a person lives with the disease without it getting worse.

Participants in the study may also receive mRNA-4157, which is an intramuscular injection, meaning it is administered directly into a muscle. The study is designed as a randomized and double-blind trial, which means participants are assigned to different treatment groups by chance, and neither the participants nor the researchers know which specific treatment is being given during the course of the study. This approach helps ensure that the results are as objective as possible.

The study is divided into two parts to determine the best way to use these medicines. In the first part, different amounts of the drugs are given to find the safest and most effective dose. The second part focuses on finding the optimal dose and observing how well the combination works for different types of lung cancer. Throughout the process, the safety and how the body processes the drugs are closely monitored.

The study is divided into different parts. The first part will test different dose levels of the investigational medications to find the most suitable dose for further testing. During this phase, doctors will carefully monitor participants for any side effects. The following parts of the study will test the chosen dose in larger groups of people with advanced non-small cell lung cancer to better understand how well the treatment works and how safe it is. Throughout the study, participants will receive the medications through infusion into a vein. Doctors will regularly check how the cancer responds to treatment using imaging scans and other assessments.

During the study, participants will need to provide a tissue sample from their tumor, either from a previously stored sample or from a new biopsy if needed. The study will track various aspects of participant health and treatment response, including any side effects that occur, whether the cancer shrinks or stops growing, and how long any positive effects last. Blood samples will be collected at different times to measure the levels of the investigational medications in the body and to check whether the immune system develops a response to these medications.

The purpose of this study is to see how well these treatment combinations work against the lung cancer in patients who have the specific EGFR mutations. The study will look at whether the treatments can slow down or stop the cancer from growing or spreading. Patients in the study will receive their assigned treatment combination and will be monitored regularly by the doctors to check how the cancer is responding and to watch for any side effects. The study is designed as an open-label trial, which means that both the patients and the doctors will know which treatment is being given.

During the study, patients will have regular visits where doctors will perform tests and examinations to measure the size of the cancer and see if it is getting smaller, staying the same, or growing. The study will follow patients for several years to gather information about how long the treatment keeps the cancer under control and how patients feel while taking the medications. This information will help doctors understand whether these treatment combinations could be useful options for patients with this type of lung cancer in the future.

The purpose of the study is to find out if adding BMS-986504 to pembrolizumab and chemotherapy can help people with this type of lung cancer live longer without their cancer getting worse, and to see if it can help them live longer overall, compared to treatment with placebo plus pembrolizumab and chemotherapy. The study will also look at how well the cancer responds to treatment and how long any response lasts, as well as checking for any unwanted effects that the treatments may cause.

The study will be conducted in two phases. Participants will be randomly assigned to receive either BMS-986504 or placebo, both given together with pembrolizumab and chemotherapy. The specific chemotherapy medicines used will depend on the type of lung cancer each person has. Throughout the study, doctors will perform regular check-ups and scans to see how the cancer is responding to treatment and to monitor for any side effects. Treatment will continue for as long as it is helping and not causing unacceptable side effects.

The main purpose of this study is to determine how well zelenectide pevedotin works in treating patients whose tumors have this specific NECTIN4 amplification. The medication is a type of drug called a bicyclic peptide, which is designed to target specific cancer cells. The study will include patients with two different types of non-small cell lung cancer: squamous and non-squamous forms of the disease.

During the study, participants will receive zelenectide pevedotin through intravenous infusion. The treatment will be given in cycles, with regular medical check-ups to monitor the patient’s health and how well the treatment is working. The maximum dose that can be given is 6 milligrams per square meter of body surface area. The study team will track if the tumors shrink, stay the same size, or grow during the treatment period.

The purpose of this research is to evaluate how well these treatments work in treating advanced non-squamous non-small cell lung cancer and to assess their safety. The study specifically includes patients whose cancer has progressed after receiving both platinum-based chemotherapy and immunotherapy treatments. The treatment period may last up to 24 months, during which patients will receive regular doses of one of the study medications.

Throughout the study, participants will undergo regular medical evaluations to monitor their response to treatment and any side effects. The research team will track various aspects of the participants’ health, including how the tumor responds to treatment, how long the response lasts, and how long patients survive without their disease getting worse. The study will use specialized imaging to measure changes in tumor size and assess the effectiveness of the treatment.

The main purpose of this study is to determine how well these treatments work in fighting lung cancer and to evaluate their safety when used individually. The medications will be administered over a period of up to 24 months, with different dosing schedules for each drug. Raludotatug Deruxtecan will be given at doses up to 5.6 mg per kilogram of body weight, Ifinatamab Deruxtecan at doses up to 12 mg per kilogram, and Docetaxel at doses up to 75 mg per square meter of body surface area.

During the study, doctors will monitor how the cancer responds to treatment and track any side effects that may occur. The study will measure how many patients’ tumors shrink or disappear, how long the treatment effects last, how long patients live without their cancer getting worse, and overall survival time. This research is part of a larger study called KEYMAKER-U01, which is investigating various treatment options for lung cancer.

For breast cancer patients, the study involves receiving Atorvastatin alongside standard immunotherapy and chemotherapy before surgery. For lung cancer patients, Atorvastatin will be given with first-line immunotherapy. The researchers will collect tumor samples and blood samples at different timepoints to analyze how the combination treatment affects the immune response in the tumor and the presence of cancer DNA in the blood.

The trial will monitor both how well the treatment works against the cancer and any side effects that may occur. Various advanced laboratory techniques will be used to understand how Atorvastatin affects the immune system’s response to cancer and to identify markers that might predict which patients will benefit most from this combination approach.

The main goal of the study is to determine if the combination of nivolumab and relatlimab with chemotherapy is more effective in extending the lives of patients compared to pembrolizumab with chemotherapy. The study will also look at other factors, such as how long the cancer stays under control and the overall response to the treatments. Participants will be monitored for any side effects from the medications.

The study will take place over several years, with the estimated completion date in 2027. Participants will be randomly assigned to one of the two treatment groups and will receive their assigned treatment as part of the study. The results will help determine the best first-line treatment option for people with this type of lung cancer.

The purpose of the study is to evaluate the safety and effectiveness of BNT327 when used with chemotherapy. The trial is divided into two phases: Phase II and Phase III. In Phase II, the focus is on assessing how safe and tolerable BNT327 is at different dose levels when combined with chemotherapy. In Phase III, the study will compare the effectiveness of BNT327 combined with chemotherapy to the combination of pembrolizumab and chemotherapy. The study will also look at how these treatments affect the progression of the disease and overall survival of participants.

Participants in the study will receive treatment over a period of time, with regular follow-up visits to monitor their health and the effects of the treatment. The study aims to provide valuable information on the potential benefits and risks of using BNT327 in treating non-small cell lung cancer, which could lead to new treatment options for patients in the future.

The purpose of this study is to evaluate the safety and effectiveness of the combination of ABBV-400 and Budigalimab in patients with advanced or metastatic non-squamous NSCLC. Participants in the study will receive these medications through an intravenous infusion, which means the drugs are given directly into the bloodstream through a vein. The study will monitor participants for any side effects and changes in their cancer to determine the best dose for future studies.

Throughout the study, participants will be closely observed to assess how their cancer responds to the treatment. The study aims to find out if this combination can help control the disease and improve the quality of life for patients with this type of lung cancer. The trial will continue until the researchers gather enough information to understand the treatment’s impact on the disease.

Participants in the study will receive the treatment as a first-line therapy, meaning it is the first treatment they will receive for their cancer. The study will monitor how well the treatment works over time, including how long patients live without their disease getting worse. The treatment with osimertinib is taken orally in the form of film-coated tablets, while the chemotherapy drugs are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The study will take place over a period of time, with regular check-ups to see how the patients are responding to the treatment. The goal is to understand if this combination of medications can help improve the outcomes for patients with this specific type of lung cancer. The study will also look at the safety of the treatment and any side effects that may occur. This research is important for finding better ways to treat patients with NSCLC who have these specific EGFR mutations.

The purpose of the study is to compare the continuation of treatment with these two medications against simply observing patients after an initial six-month treatment period. This is done to see if continuing the treatment provides better outcomes for patients with stage IV NSCLC, which is an advanced form of lung cancer. The study aims to understand if continuing the treatment helps in delaying the progression of the disease.

Participants in the study will first receive a combination of YERVOY and OPDIVO for six months. After this initial treatment, some participants will continue receiving the medications, while others will be observed without further treatment. The study will monitor the participants’ health and the progression of their cancer over time. The goal is to determine the best approach for managing this type of lung cancer and to improve the quality of life and survival rates for patients.

The purpose of the study is to determine if the combination of atezolizumab and bevacizumab can improve the overall survival of patients compared to using atezolizumab alone. Patients participating in the study will receive one of these treatments and will be monitored over a period of time to assess their health and response to the treatment. The study aims to provide valuable information on the effectiveness of these treatments for patients with this specific type of lung cancer.

Participants in the study will be randomly assigned to receive either the single medication or the combination treatment. The study will continue for a set period, during which patients will receive regular infusions and follow-up assessments to track their progress. This research is important for understanding how these treatments can help improve the lives of people with advanced non-small-cell lung cancer.

The purpose of the study is to determine how effective Atezolizumab is when used alongside Carboplatin and Paclitaxel in improving the overall survival of patients. Participants in the study will receive these medications through an infusion, which means the drugs are given directly into the bloodstream through a vein. The study will compare the survival rates of patients receiving the standard treatment with those receiving the experimental combination of Atezolizumab, Carboplatin, and Paclitaxel.

The study will take place over a period of time, with patients receiving treatment and being monitored for their response to the medication. The goal is to see if the combination of these drugs can help patients live longer and manage their cancer more effectively. The study will also look at other factors such as how long patients live without the cancer getting worse and the overall response to the treatment.

The purpose of the study is to compare the effects of the combination of CC-486 and pembrolizumab against pembrolizumab with a placebo in patients with NSCLC. Participants in the study will be randomly assigned to receive either the combination treatment or pembrolizumab with a placebo. The study will monitor the participants over a period to assess how well the treatments work and to check for any side effects. The trial will help researchers understand if the combination of CC-486 and pembrolizumab can improve outcomes for patients with this type of lung cancer.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to track the progress of their treatment. The study is expected to continue until 2025, providing valuable information on the potential benefits and risks of using CC-486 in combination with pembrolizumab for treating advanced NSCLC. This research could lead to new treatment options for patients with this challenging form of lung cancer.

The study will involve patients receiving Durvalumab through an infusion, which is a method of delivering medication directly into the bloodstream. The treatment will be given over a period of up to 24 months. During the study, researchers will monitor the patients’ health and any side effects they may experience. The goal is to see if Durvalumab can improve the patients’ overall health and extend their survival.

This trial is particularly important because it includes patients who are often not eligible for other clinical trials due to their poor health status. By participating in this study, researchers hope to find out if Durvalumab can be a safe and effective treatment option for these patients, potentially leading to better outcomes and longer lives.

Participants in the study will receive either the cancer vaccine or the chemotherapy drug. The cancer vaccine, OSE2101, is given as an injection under the skin, while docetaxel is administered through an intravenous infusion, which means it is given directly into a vein. The study will last for up to 24 months, during which time the health and progress of the participants will be closely monitored by the research team. The main goal is to see which treatment helps patients live longer, regardless of the cause of death.

This study is important for patients with NSCLC who have not responded to previous immune therapy treatments. By comparing the cancer vaccine with chemotherapy, researchers hope to find a more effective treatment option for these patients. The trial will provide valuable information on the safety and effectiveness of OSE2101 compared to docetaxel, potentially leading to better treatment strategies for this type of lung cancer.

The purpose of the study is to evaluate how well the combination of encorafenib and binimetinib works in patients with this type of lung cancer. Participants in the study will take these medications orally, meaning they will swallow them in the form of capsules and tablets. The study will last for a period of up to 60 days, during which the effects of the treatment will be closely monitored.

Throughout the study, researchers will assess the response of the cancer to the treatment, looking for any signs of improvement or progression. The study aims to provide valuable information on the potential benefits of using these medications together for patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer.

The study is divided into different parts. Initially, all participants will receive the treatment to see how well it is tolerated. After this, participants will be randomly assigned to receive either the combination of GB1211 and atezolizumab or atezolizumab with a placebo. This part of the study is conducted without participants knowing which treatment they are receiving. The study will also include an extension phase to observe the long-term effects of the treatment.

Participants will take part in regular check-ups and assessments to monitor their health and the progress of their cancer. The study aims to provide valuable information on whether the combination of GB1211 and atezolizumab can improve outcomes for patients with NSCLC. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the treatment’s safety and effectiveness over time.

The study is divided into three parts. In Part A, patients with advanced solid tumors or lymphomas will receive OSE-279 to determine the best dose. In Part B, the safety and tolerability of the combination of OSE-279 and TEDOPI will be evaluated in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) who have a specific genetic marker called HLA-A2. In Part C, the effectiveness of the combination treatment will be compared to OSE-279 alone in patients with the same type of lung cancer. The study will involve regular visits to the clinic for treatment and monitoring over a period of time.

Throughout the study, patients will receive either the study medications or a placebo. The study aims to assess how well the treatments work in terms of reducing the size of the tumors and improving the overall response rate. The study will also monitor any side effects experienced by the participants to ensure the treatments are safe. The trial is expected to continue until 2029, with the goal of finding new and effective treatment options for these types of cancer.

Participants in the study will receive either Ensartinib or Crizotinib. The study will monitor the progress of the disease and any side effects experienced by the participants. The trial will last for a period of time, during which participants will have regular check-ups and assessments to track their health and the cancer’s response to the treatment. The study aims to determine which medication is more effective in controlling the cancer and improving the quality of life for patients.

This trial is important for understanding the best treatment options for patients with ALK-positive NSCLC. By comparing these two medications, researchers hope to find the most effective way to manage this type of lung cancer and provide better outcomes for patients. Participants will be closely monitored throughout the study to ensure their safety and to gather valuable information about the treatments being tested.

The study is divided into several parts. In some parts, patients will receive tisotumab vedotin alone, while in others, it will be given alongside pembrolizumab or both pembrolizumab and a platinum agent like cisplatin or carboplatin. These medications are administered through an intravenous infusion, which means they are given directly into the bloodstream through a vein. The study will observe the effects of these treatments over time to understand their impact on the cancer and any side effects that may occur.

The purpose of this study is to assess the antitumor activity of tisotumab vedotin and its combinations in treating these advanced cancers. The study will monitor how the tumors respond to the treatment, how long it takes for a response to occur, and the overall survival of the patients. This information will help determine the effectiveness and safety of the treatment options being tested.

The purpose of the study is to determine if the combination of Niraparib and Pembrolizumab can help patients live longer without the disease getting worse, and to see if it can improve overall survival compared to the placebo. Participants in the study will have already received a first-line treatment with platinum-based chemotherapy and Pembrolizumab, and their disease should have either remained stable or shown improvement. The study will involve regular monitoring and assessments to track the progress of the disease and the effects of the treatment.

Throughout the study, participants will receive either the combination of Niraparib and Pembrolizumab or a placebo with Pembrolizumab. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The study will continue for a set period, during which participants will be closely monitored for any changes in their condition and any side effects they may experience. The ultimate goal is to find a more effective maintenance therapy for patients with advanced or metastatic NSCLC.

The purpose of the study is to see how effective sotorasib is in reducing the size of tumors in patients with this type of lung cancer. Participants in the study will receive sotorasib and will be monitored over time to observe changes in their tumor size and overall health. The study will also look at how long patients can live without their disease getting worse and how long they respond to the treatment. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of sotorasib.

Throughout the study, various health assessments will be conducted to ensure the safety and well-being of the participants. These assessments will include monitoring for any side effects, changes in vital signs, and laboratory tests. The study aims to gather information on how sotorasib affects patients with different health conditions and how it interacts with other treatments they may have received. The trial is expected to continue until 2028, providing valuable insights into the treatment of KRAS G12C-mutated non-small cell lung cancer.

The main purpose of this research is to evaluate how well the combination of these medications works in treating this type of lung cancer. The study will track how patients respond to treatment over time, including how the cancer responds and what side effects may occur. Some patients will receive brigatinib alone, while others will receive brigatinib together with carboplatin and pemetrexed.

During the study, patients will receive regular medical check-ups and undergo various tests to monitor their health and how well the treatment is working. The treatment period may last up to 60 months, with regular assessments of the cancer’s response to treatment. The medications will be given in specific doses, with brigatinib taken daily as tablets, while carboplatin and pemetrexed will be given through an intravenous line at scheduled intervals.

The purpose of the study is to evaluate how well this combination works in patients whose cancer has progressed outside the brain while on Lorlatinib. The study will involve taking Lorlatinib in the form of film-coated tablets, and the chemotherapy drugs, which include Carboplatin, Cisplatin, and Pemetrexed, will be administered as solutions for infusion, meaning they are given directly into the bloodstream through a vein. The study will follow participants over a period to monitor the progression of the disease and any side effects experienced.

Participants will receive the treatment and be monitored regularly to assess the impact on their cancer and overall health. The study aims to provide insights into whether this combination of treatments can help manage the disease more effectively compared to previous data. The trial will also collect information on the quality of life of participants and any adverse effects they may experience during the treatment period.

The purpose of this study is to see if the combination of nivolumab and ipilimumab with chemotherapy is more effective than chemotherapy alone for patients with Stage IV NSCLC. Participants in the study will receive either the combination treatment or chemotherapy by itself. The study will monitor the participants over time to assess the effectiveness of the treatments in terms of survival and response to the therapy.

Throughout the study, participants will receive their treatments through an intravenous (IV) infusion, which means the medication is given directly into a vein. The study aims to provide valuable information on whether adding nivolumab and ipilimumab to chemotherapy can improve outcomes for patients with advanced lung cancer. The trial is expected to continue until 2025, allowing researchers to gather comprehensive data on the long-term effects and benefits of the treatment combinations.

Participants in the study will be randomly assigned to one of two groups. One group will receive Ociperlimab in combination with Tislelizumab, while the other group will receive Pembrolizumab followed by a placebo. The treatments are given as infusions, which means they are administered directly into the bloodstream through a vein. The study will monitor the participants over a period of time to assess the effectiveness of the treatments in improving survival rates.

The trial aims to provide valuable information on how these treatments can help patients with non-small cell lung cancer. By comparing the different treatment options, researchers hope to find the most effective approach for managing this type of cancer. The study will also look at the quality of life of participants and any side effects they may experience during the trial.

Participants in the study will receive brigatinib and their response to the treatment will be monitored over time. The study will look at how well the cancer responds to the medication, including how long the response lasts and how the treatment affects cancer that may have spread to the brain. The safety and tolerability of brigatinib will also be assessed to ensure it is safe for patients to use.

The study will involve regular check-ups and assessments to track the progress of the treatment. This will help researchers gather important information about the effectiveness of brigatinib in treating ALK-positive non-small cell lung cancer and its impact on patients’ overall health and survival. The study is expected to continue until 2027, providing valuable insights into the treatment of this type of lung cancer.

Participants in the study will receive the combination of INCB099280 and Adagrasib to see how their bodies respond to the treatment. The study will monitor for any side effects and determine the most suitable dose for patients. The trial will also look at how the medications are processed in the body and their effects on the tumors.

The study is designed to help understand the potential benefits and risks of using these medications together for treating Advanced Solid Tumors with the KRASG12C mutation. Participants will be closely monitored throughout the study to ensure their safety and to gather important information about the treatment’s effectiveness.

The purpose of this study is to compare two different ways of giving pembrolizumab: as a subcutaneous injection (under the skin) and as an intravenous infusion (through a vein). Participants will receive pembrolizumab along with one of the chemotherapy drugs as part of their first-line treatment, which means it is the first treatment given for their cancer. The study will help determine how the body processes pembrolizumab when given in these two different ways and will also look at the safety of these treatments.

Participants in the study will receive treatment over a period of time, with regular visits to the clinic for their medication and monitoring. The study will track how well the cancer responds to the treatment and any side effects that may occur. This information will help doctors understand the best way to use pembrolizumab in combination with chemotherapy for treating metastatic non-small cell lung cancer.

The purpose of the study is to evaluate the effectiveness of these medication combinations in treating advanced non-small cell lung cancer. Participants in the study will receive one or more of these medications, and some may receive a placebo. The study will monitor how the cancer responds to the treatment over time. The trial will last for a period of up to 24 months, during which participants will have regular check-ups and assessments to track their progress and any side effects they may experience.

This study aims to provide valuable information on how these medication combinations can help manage advanced non-small cell lung cancer. By participating, individuals contribute to research that may improve treatment options for this disease in the future. The study will also collect data on the safety of these treatments and how they affect the overall health and well-being of participants.

The purpose of this study is to compare the effectiveness of different treatment combinations in improving the survival of patients with this type of lung cancer. Participants will receive a combination of Pembrolizumab with either Pemetrexed and a platinum-based drug (Carboplatin or Cisplatin) or Olaparib. After the initial treatment phase, participants will continue with either Olaparib or Pemetrexed as maintenance therapy. Some participants may receive a placebo during the maintenance phase to help researchers understand the effects of the medications better.

The study will take place over several months, with regular check-ups and assessments to monitor the participants’ health and the cancer’s response to the treatment. The goal is to determine which combination of treatments offers the best outcomes in terms of slowing down the progression of the cancer and improving overall survival. Participants will be closely monitored for any side effects or changes in their condition throughout the study.